SUN BIOPHARMA INC (SNBP) financial statements (2021 and earlier)

Company profile

Business Address 712 VISTA BLVD #305
WACONIA, MN 55387
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9210010
Cash and cash equivalents9210010
Receivables0000010
Prepaid expense0000000
Deferred tax assets    (0)
Other undisclosed current assets      0
Total current assets:10321120
Noncurrent Assets
Property, plant and equipment      0
Other noncurrent assets000  0 
Other undisclosed noncurrent assets      0
Total noncurrent assets:000  00
TOTAL ASSETS:10321120
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1114210
Accounts payable1111110
Accrued liabilities1001110
Employee-related liabilities   1   
Interest and dividends payable  0000 
Debt 000000
Deferred revenue and credits   0
Other undisclosed current liabilities 1003 1
Total current liabilities:1224611
Noncurrent Liabilities
Long-term debt and lease obligation   0 00
Long-term debt, excluding current maturities   0 0 
Capital lease obligations    0
Other undisclosed noncurrent liabilities     3 
Total noncurrent liabilities:   0 30
Total liabilities:1224641
Stockholders' equity
Stockholders' equity attributable to parent810(4)(5)(3)(0)
Preferred stock      0
Common stock0000000
Additional paid in capital55423526141113
Accumulated other comprehensive income (loss)(0)00(0)00 
Accumulated deficit(46)(41)(35)(29)(19)(14)(14)
Total stockholders' equity:810(4)(5)(3)(0)
TOTAL LIABILITIES AND EQUITY:10321120

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues      1
Cost of revenue      (1)
Cost of goods and services sold      (1)
Gross profit:      1
Operating expenses(6)(4)(4)(6)(5)(5)(1)
Other undisclosed operating loss      (0)
Operating loss:(6)(4)(4)(6)(5)(5)(0)
Nonoperating income (expense)1(2)(2)(5)(0)(0) 
Other nonoperating income (expense)1(0)(1)0(0)(0) 
Interest and debt expense(0)(2)(2)(4)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes022400 
Loss from continuing operations before income taxes:(5)(7)(6)(11)(5)(6)(0)
Income tax expense (benefit)000101(0)
Other undisclosed income from continuing operations      0
Net loss:(5)(6)(6)(10)(5)(5)(0)
Other undisclosed net loss attributable to parent      (0)
Net loss available to common stockholders, diluted:(5)(6)(6)(10)(5)(5)(0)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(5)(6)(6)(10)(5)(5)(0)
Comprehensive loss:(5)(6)(6)(10)(5)(5)(0)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)00(0)00 
Comprehensive loss, net of tax, attributable to parent:(5)(6)(5)(11)(5)(5)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: